Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based Angel Biotechnology Holdings has signed a second manufacturing contract, valued at approximately GBP640,000, with Russia-based Materia Medica Holding, for process development and GMP manufacture of polyclonal antibodies.
Subscribe to our email newsletter
Gordon Sherriff, COO of Angel Biotechnology, said: “We are delighted that Materia Medica, a leading Russian pharmaceutical company, has decided to award a second contract to Angel, so quickly after signing the first contract. This confirms Angel’s ability to provide our clients with the essential quality, delivery and value for money they need from their chosen contract manufacturer. We look forward to this being the second in a long line of contracts with Materia Medica.”
Sergey Tarasov, of R&D department at Materia Medica Holding, said: “Following the successful initiation of the first contract, we are very pleased to award a second GMP manufacturing contract to Angel Biotechnology. We are now building a fruitful, long-term relationship with Angel, establishing them as our manufacturer of choice for future projects.”